Epigenic Therapeutics
- Biotech or pharma, therapeutic R&D
Epigenic Therapeutics developed two groundbreaking technologies - epigenetic modulation (next-wave gene therapy), and in-vivo LNP delivery. We seek partnership on our pipelines and platform technologies.
Pipeline focuses on EPI-001 (PCSK9, next-generation product) with a only single dosing and even stronger efficacy vs. other modalities, preliminary exciting clinical data is available;
EPI-003 (HBV) silencing cccDNA and integrated DNA from root cause via epigenetic modulation with preliminary promising clinical data;
EPI-004 (Obesity) with novel mechanism to address weight rebound and muscle loss.
Technology focuses on empowering collaborators to develop allogeneic cell therapy using our epigenetic modulation technology, and in-vivo targeting therapies using our in-vivo LNP delivery, e.g. T cell targeting, hematopoietic stem cell targeting.
We are also open to research collaborations who intends to develop nominated targets with our novel technology.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}